Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
C-Rad ABFRA:24C -4.59%92 Days Payable is 86.07 as of Jun. 2026, which is 10% above its 10-year median of 78.05. GuruFocus rates FRA:24C with a GF Score™ of 92/100 and a GF Value™ of €2.80. The stock has 4 warning signs investors should review. Among 794 Medical Devices & Instruments companies, C-Rad AB ranks better than 56.05% on this metric.
C-Rad AB's average Accounts Payable for the
three
months ended in Jun. 2026 was €2.62 Mil. C-Rad AB's Cost of Goods Sold for the
three
months ended in Jun. 2026 was €2.78 Mil.
Hence, C-Rad AB's Days Payable for the
three
months ended in Jun. 2026 was 86.07.
The historical rank and industry rank for C-Rad AB's Days Payable or its related term are showing as below:
FRA:24C'
s Days Payable Range Over the Past 10 Years
Min: 41.98 Med: 78.05 Max: 101.96
Current: 77.52
During the past 13 years, C-Rad AB's highest Days Payable was 101.96. The lowest was 41.98. And the median was 78.05.
FRA:24C's Days Payable is ranked better than 56.05% of 794
companies
in the Medical Devices & Instruments industry
Industry Median: 67.97
vs FRA:24C: 77.52
C-Rad AB's Days Payable
increased
from Jun. 2025 (56.76) to Jun. 2026 (86.07).
It may suggest that C-Rad ABdelayed paying its suppliers.
C-Rad AB Days Payable Related Terms
C-Rad AB Days Payable Historical Data
* Premium members only.
The historical data trend for C-Rad AB's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, C-Rad AB's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
C-Rad AB Days Payable vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, C-Rad AB's Days Payable distribution charts can be found below:
* The bar in red indicates where C-Rad AB's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
C-Rad AB's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
C-Rad AB (FRA:24C) has a Days Payable of 86.07 as of Jun. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on C-Rad AB and its competitors. This is 10% above median its historical median of 78.05. Over the past decade, C-Rad AB's Days Payable has ranged from 41.98 to 101.96. According to the industry distribution chart, C-Rad AB ranks #349 out of 794 companies in the Medical Devices & Instruments industry, placing it in the top 44%.
Is C-Rad AB's Days Payable too high?
C-Rad AB's current Days Payable of 86.07 is 10% above median its 10-year median of 78.05. Over the past 10 years, this metric has ranged from a low of 41.98 to a high of 101.96. The Medical Devices & Instruments industry median Days Payable is 67.97. C-Rad AB's value of 86.07 is 26.6% above this industry median. Based on the distribution chart, C-Rad AB ranks #349 out of 794 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, C-Rad AB has a GF Score™ of 92/100, reflecting its overall financial health beyond just this single metric.
How does C-Rad AB's Days Payable compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, C-Rad AB ranks #349 out of 794 companies for Days Payable. This puts C-Rad AB in the upper half of its industry. The industry median Days Payable is 67.97. C-Rad AB's value of 86.07 is 26.6% above this benchmark. Historically, C-Rad AB's own Days Payable has ranged from 41.98 to 101.96 over the past decade. While the company's 10-year median is 78.05 vs. the industry median of 67.97, C-Rad AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Devices & Instruments company?
The median Days Payable among Medical Devices & Instruments companies is 67.97, based on 794 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. C-Rad AB's current Days Payable of 86.07 is 26.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on C-Rad AB and its competitors. For the Medical Devices & Instruments industry, the median Days Payable is 67.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. C-Rad AB's current Days Payable is 86.07, which is 10% above median its own 10-year median of 78.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is C-Rad AB stock overvalued right now?
C-Rad AB (FRA:24C) has a current Days Payable of 86.07. The stock's GF Value™ is €2.80, compared to a current price of €3.12 — trading 11.4% above its estimated fair value. The current Days Payable is 86.07, which is 10% above median its 10-year median of 78.05 and 26.6% above the Medical Devices & Instruments industry median of 67.97. C-Rad AB's overall GF Score™ is 92/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For C-Rad AB (FRA:24C), the current Days Payable is 86.07 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is C-Rad AB (FRA:24C) Overvalued in 2026?
Based on GuruFocus' analysis, C-Rad AB stock appears to be overvalued.
The current stock price of €3.12 is trading 11.4% above its estimated GF Value™ of €2.80.
Key valuation signals for FRA:24C:
Days Payable: 86.07 (10% above median its 10-year median of 78.05)
GF Value™: €2.80 vs. price of €3.12 (11.4% above fair value)
Industry Position: 26.6% above the Medical Devices & Instruments median (#349 of 794)
No single metric tells the full story. See the FRA:24C stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
C-Rad AB is a Sweden-based company engaged in the development and sales of systems with applications in radiation therapy for the treatment of cancer. The systems can be used to position the patient before the treatment and to localize and monitor the tumor by recording information such as patient movements during radiation treatment. Its product portfolio includes the Catalyst and Sentinel systems. Geographically, the company generates a majority of its revenue from Asia Pacific region, and also has its presence in Europe, Middle East and Africa and the rest from Americas.
92GF Score
Get the complete analysis for FRA:24C
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:24C has been successfully added to your 
